All In Biotech

Drug Trial Radar · NCT07741045

Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 5, 2026

Primary completion

Jan 15, 2028

Study completion Nov 15, 2028

Sponsor

Lead sponsor
Hangzhou PhecdaMed Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients. This study plans to enroll approximately 300 EOPD participants, who will be randomized in a 1:1 ratio to two cohorts (Cohort 1: 200 mg dose group; Cohort 2: 400 mg dose group). Within each cohort, successfully screened participants will be stratified by stable use of dopamine receptor agonists (Yes vs. No) and stable use of Monoamine Oxidase B (MAO-B) inhibitors (Yes vs. No), and within each stratum, randomized in a 2:1 ratio to the TJ0113 Capsules group and the placebo group, with approximately 100 assigned to the TJ0113 Capsules group and approximately 50 assigned to the placebo group. In this trial, the sample size for the TJ0113 Capsules 200 mg group, TJ0113 Capsules 400 mg group, and placebo group will each be approximately 100 participants. After randomization, during the double-blind treatment period, participants will receive continuous oral administration of TJ0113 Capsules or placebo for 26 weeks. After the double-blind treatment ends, participants will enter the open-label treatment period. During the open-label treatment period, all participants will receive oral TJ0113 Capsules for 26 weeks, and the dose of TJ0113 Capsules will be consistent with the dose of the investigational product taken by the participant during the double-blind treatment period (regardless of whether they took TJ0113 Capsules or placebo during the double-blind treatment period). After the open-label treatment period ends, participants will continue to receive a safety follow-up for 1 week (telephone follow-up). From the screening period to the end of the double-blind treatment period, all participants must maintain their original background anti-PD medication regimen unchanged; from the open-label treatment period to the end of the study, changes to the dose of stably received anti-PD medications are discouraged, but if necessary, the dose may be adjusted at the discretion of the investigator.

Conditions

  • Parkinson's Disease (PD)
  • Parkinson Disease 6, Early-Onset

Interventions

  • TJ0113 200mgDrug

    100 mg Capsule, 2 Capsules Once Daily

  • TJ0113 400mgDrug

    100 mg Capsule, 4 Capsules Once Daily

  • PlaceboDrug

    2 Capsules or 4 Capsules, Once Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score in off-anti-PD medication state at Week 26. "Off-anti-PD medication state" is defined as: ≥12 hours after the last dose of anti-PD medicationTime frame: After 26 weeks of treatment

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • The Third Xiangya Hospital, Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China · Not yet recruiting

  • General Hospital of Nuclear Industry (The Second Affiliated Hospital of Soochow University)

    Suzhou, Jiangsu, China · Not yet recruiting

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The Affiliated Hospital of Hangzhou Normal University

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Huzhou Central Hospital

    Huzhou, Zhejiang, China · Recruiting

  • Jiaxing Second Hospital

    Jiaxing, Zhejiang, China · Recruiting

  • Lishui Municipal People's Hospital

    Lishui, Zhejiang, China · Not yet recruiting

  • Taizhou Central Hospital

    Taizhou, Zhejiang, China · Not yet recruiting

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China · Recruiting

  • Wenzhou Central Hospital

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.